Computed tomographic perfusion to Predict Response to Recanalization in ischemic stroke.
Computed tomographic perfusion to Predict Response to Recanalization in ischemic stroke.
复制标题
DOI：
10.1002/ana.24953
复制
发表时间：
2017-06
影响因子：
11.2
通讯作者：
CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project (CRISP) Investigators
中科院分区：
文献类型：
--
作者：
Lansberg MG;Christensen S;Kemp S;Mlynash M;Mishra N;Federau C;Tsai JP;Kim S;Nogueria RG;Jovin T;Devlin TG;Akhtar N;Yavagal DR;Haussen D;Dehkharghani S;Bammer R;Straka M;Zaharchuk G;Marks MP;Albers GW;CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project (CRISP) Investigators
To assess the utility of CT perfusion for selection of patients for endovascular therapy up to 18 hours after symptom onset. We conducted a multicenter cohort study of consecutive acute stroke patients scheduled to undergo endovascular therapy within 90 min after a baseline CTP. Patients were classified as ‘target mismatch’ if they had a small ischemic core and a large penumbra on their baseline CT perfusion. Reperfusion was defined as >50% reduction in critical hypoperfusion between the baseline CT perfusion and the 36-hour follow-up MRI. Of the 201 patients enrolled, 190 patients with an adequate baseline CT perfusion study who underwent angiography were included; mean age 66 years, median NIHSS 16, median time from symptom onset to endovascular therapy 5.2 hours. Rate of reperfusion was 89%. In patients with target mismatch (n=131), reperfusion was associated with higher odds of favorable clinical response, defined as an improvement of ≥8 points on the NIH Stroke Scale (83% vs 44%, p=0.002; adjusted OR=6.6; 95% CI 2.1–20.9). This association did not differ between patients treated within 6 hrs (OR = 6.4; 95% CI 1.5–27.8) and those treated beyond 6 hrs after symptom onset (OR = 13.7; 95% CI 1.4–140). The robust association between endovascular reperfusion and good outcome among patients with the CT perfusion target mismatch profile treated up to 18 hours after symptom onset supports a randomized trial of endovascular therapy in this patient population.
登录
查看更多内容
影响因子：
6.7
作者：
Churilov, Leonid;Arnup, Sarah;Donnan, Geoffrey A.
通讯作者：
Donnan, Geoffrey A.
影响因子：
9.9
作者：
Lansberg, Maarten G.;Cereda, Carlo W.;Albers, Gregory W.
通讯作者：
Albers, Gregory W.
影响因子：
158.5
作者：
Berkhemer, O. A.;Fransen, P. S. S.;Dippel, D. W. J.
通讯作者：
Dippel, D. W. J.
DOI：
10.1016/s1474-4422(14)70066-3
发表时间：
2014-06
期刊：
The Lancet. Neurology
影响因子：
--
作者：
Khatri P;Yeatts SD;Mazighi M;Broderick JP;Liebeskind DS;Demchuk AM;Amarenco P;Carrozzella J;Spilker J;Foster LD;Goyal M;Hill MD;Palesch YY;Jauch EC;Haley EC;Vagal A;Tomsick TA;IMS III Trialists
通讯作者：
IMS III Trialists
影响因子：
8.3
作者：
Borst, Jordi;Berkhemer, Olvert A.;Majoie, Charles B. L. M.
通讯作者：
Majoie, Charles B. L. M.